<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">        <PMID Version="1">30404788</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>08</Day>        </DateRevised>        <Article PubModel="Electronic-Print">            <Journal>                <ISSN IssnType="Print">2291-0026</ISSN>                <JournalIssue CitedMedium="Print">                    <Volume>6</Volume>                    <Issue>4</Issue>                    <PubDate>                        <MedlineDate>2018 Oct-Dec</MedlineDate>                    </PubDate>                </JournalIssue>                <Title>CMAJ open</Title>                <ISOAbbreviation>CMAJ Open</ISOAbbreviation>            </Journal>            <ArticleTitle>Screening for a new primary cancer in patients with existing metastatic cancer: a retrospective cohort study.</ArticleTitle>            <Pagination>                <MedlinePgn>E538-E543</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.9778/cmajo.20180045</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cancer screening aims to detect malignant disease early in its natural history when interventions might improve patient outcomes. Such benefits are unclear when screening occurs for patients with an existing high risk of death. Our aim was to study the extent of routine cancer screening for a new primary cancer in patients with existing metastatic cancer.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">We used administrative databases from Ontario to identify a retrospective cohort of adults of eligible screening age (â‰¥ 50 yr) who had a diagnosis of stage IV (metastatic) colorectal, lung, breast or prostate cancer between 2007 and 2012. We calculated the cumulative incidence of cancer screening over time for colorectal and breast cancer.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Among the 20 992 patients with metastatic lung, breast or prostate cancer, 2.9%, 6.3% and 13.3% of patients, respectively, underwent testing for colorectal cancer within 1 year of cancer diagnosis. Within 3 years of diagnosis, rates reached 4.1%, 12.3% and 27.5%, respectively (8.5% of all patients). Incidence of colorectal cancer testing was higher among patients who received their diagnoses more recently compared with patients with diagnoses from earlier time periods (<i>p</i> = 0.0143). Among the 10 034 women with metastatic lung or colorectal cancer, 8.7% and 8.0% of patients, respectively, underwent breast cancer screening within 1 year of cancer diagnosis. Within 3 years of diagnosis, screening rates reached 10.2% and 13.1%, respectively.</AbstractText>                <AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">Our findings indicate excessive rates of cancer screening among patients with metastatic cancer who are unlikely to benefit. Further studies are warranted to identify predictors for screening, resource implications, potential and real harms borne by patients, and the impact of a recent Choosing Wisely statement recommending against the practice.</AbstractText>                <CopyrightInformation>Copyright 2018, Joule Inc. or its licensors.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Cheung</LastName>                    <ForeName>Matthew C</ForeName>                    <Initials>MC</Initials>                    <AffiliationInfo>                        <Affiliation>Odette Cancer Centre (Cheung, Singh), Sunnybrook Health Sciences Centre and University of Toronto; Institute for Clinical Evaluative Sciences (Cheung, Tinmouth, Austin, Fischer, Fung, Singh); Cancer Care Ontario (Tinmouth, Singh); Division of Gastroenterology, Department of Medicine (Tinmouth), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ont. matthew.cheung@sunnybrook.ca.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tinmouth</LastName>                    <ForeName>Jill</ForeName>                    <Initials>J</Initials>                    <AffiliationInfo>                        <Affiliation>Odette Cancer Centre (Cheung, Singh), Sunnybrook Health Sciences Centre and University of Toronto; Institute for Clinical Evaluative Sciences (Cheung, Tinmouth, Austin, Fischer, Fung, Singh); Cancer Care Ontario (Tinmouth, Singh); Division of Gastroenterology, Department of Medicine (Tinmouth), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ont.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Austin</LastName>                    <ForeName>Peter C</ForeName>                    <Initials>PC</Initials>                    <AffiliationInfo>                        <Affiliation>Odette Cancer Centre (Cheung, Singh), Sunnybrook Health Sciences Centre and University of Toronto; Institute for Clinical Evaluative Sciences (Cheung, Tinmouth, Austin, Fischer, Fung, Singh); Cancer Care Ontario (Tinmouth, Singh); Division of Gastroenterology, Department of Medicine (Tinmouth), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ont.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fischer</LastName>                    <ForeName>Hadas D</ForeName>                    <Initials>HD</Initials>                    <AffiliationInfo>                        <Affiliation>Odette Cancer Centre (Cheung, Singh), Sunnybrook Health Sciences Centre and University of Toronto; Institute for Clinical Evaluative Sciences (Cheung, Tinmouth, Austin, Fischer, Fung, Singh); Cancer Care Ontario (Tinmouth, Singh); Division of Gastroenterology, Department of Medicine (Tinmouth), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ont.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Fung</LastName>                    <ForeName>Kinwah</ForeName>                    <Initials>K</Initials>                    <AffiliationInfo>                        <Affiliation>Odette Cancer Centre (Cheung, Singh), Sunnybrook Health Sciences Centre and University of Toronto; Institute for Clinical Evaluative Sciences (Cheung, Tinmouth, Austin, Fischer, Fung, Singh); Cancer Care Ontario (Tinmouth, Singh); Division of Gastroenterology, Department of Medicine (Tinmouth), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ont.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Singh</LastName>                    <ForeName>Simron</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Odette Cancer Centre (Cheung, Singh), Sunnybrook Health Sciences Centre and University of Toronto; Institute for Clinical Evaluative Sciences (Cheung, Tinmouth, Austin, Fischer, Fung, Singh); Cancer Care Ontario (Tinmouth, Singh); Division of Gastroenterology, Department of Medicine (Tinmouth), Sunnybrook Health Sciences Centre and University of Toronto, Toronto, Ont.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Canada</Country>            <MedlineTA>CMAJ Open</MedlineTA>            <NlmUniqueID>101620603</NlmUniqueID>            <ISSNLinking>2291-0026</ISSNLinking>        </MedlineJournalInfo>        <CommentsCorrectionsList>            <CommentsCorrections RefType="ErratumIn">                <RefSource>CMAJ Open. 2018 Nov 19;6(4):E567</RefSource>                <PMID Version="1">30459174</PMID>            </CommentsCorrections>        </CommentsCorrectionsList>        <CoiStatement>Competing interests: Jill Tinmouth was the lead scientist for the ColonCancerCheck program at Cancer Care Ontario. No other competing interests were declared.</CoiStatement>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>9</Day>                <Hour>6</Hour>                <Minute>1</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30404788</ArticleId>            <ArticleId IdType="pii">6/4/E538</ArticleId>            <ArticleId IdType="doi">10.9778/cmajo.20180045</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>